Clinical Trial Update: CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial investigates a CCL21-gene modified dendritic cell vaccine in combination with pembrolizumab for stage IV non-small cell lung cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CCL21-Gene Modified Dendritic Cell Vaccine
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING